Farxiga Adolescent (12 to 17) Safety: What Patients and Parents Need to Know

FDA Approval Status for Adolescents

The FDA approved dapagliflozin (Farxiga) for use in patients aged 10 years and older with type 2 diabetes in March 2023, making it one of the first SGLT2 inhibitors cleared for a pediatric population in the United States. The approval was based on pharmacokinetic bridging data, short-term glycemic efficacy studies, and safety data extrapolated from adult trials. Adolescents aged 12 to 17 fall squarely within the approved age range.

The Regulatory Pathway

The FDA used a combination of adult efficacy data and dedicated pediatric pharmacokinetic (PK) studies to support approval. Pediatric PK modeling confirmed that 10 mg once daily in patients weighing at least 45 kg produces plasma exposures comparable to adults. For adolescents weighing <45 kg, the approved dose is 5 mg once daily, though most 12 to 17-year-olds exceed this threshold. The full prescribing information is available through FDA's accessdata portal.

What the Approval Does Not Cover

The 2023 approval covers type 2 diabetes only. Farxiga is not currently FDA-approved in adolescents for heart failure or chronic kidney disease, even though the DAPA-HF trial (NEJM 2019, N=4,744) demonstrated a 26% relative risk reduction in worsening heart failure or cardiovascular death in adults with HFrEF. Prescribing Farxiga in adolescents for those indications would be off-label.

How Dapagliflozin Works in the Adolescent Body

Dapagliflozin blocks SGLT2 receptors in the proximal tubule of the kidney, preventing reabsorption of roughly 60 to 90 g of glucose per day and excreting it in the urine. This mechanism operates independently of insulin secretion, which matters in adolescents because pancreatic beta-cell function varies considerably in youth-onset type 2 diabetes. The glucose-lowering effect does not depend on residual insulin capacity.

Pharmacokinetics in 12 to 17-Year-Olds

A dedicated PK study in pediatric patients aged 10 to 17 found that weight-normalized clearance of dapagliflozin is similar to adults once body weight exceeds approximately 45 kg. Published PK data on NCBI confirm that the 10 mg dose achieves area-under-the-curve (AUC) values within the adult reference range in most adolescents. Renal glucose excretion is proportionally similar to adults, supporting dose equivalence.

Metabolic Effects Beyond Glucose

Beyond HbA1c reduction, dapagliflozin produces modest but measurable weight loss (approximately 1.5 to 2.5 kg in adults at 24 weeks), mild blood pressure reduction (2 to 3 mmHg systolic), and a small decrease in uric acid. These secondary effects may be clinically meaningful in adolescents with comorbid obesity, hypertension, or hyperuricemia, all of which are common in youth-onset type 2 diabetes.

Efficacy Data in Adolescents and Pediatric SGLT2 Trials

Direct dapagliflozin-specific efficacy data in the 12 to 17 age band is more limited than adult data. The FDA relied partly on pharmacokinetic bridging and partly on short-term glycemic studies.

The E8C4002 Pediatric Study

AstraZeneca's pediatric study E8C4002 evaluated dapagliflozin 5 mg and 10 mg in patients aged 10 to 17 with type 2 diabetes over 24 weeks. The 10 mg dose produced a placebo-adjusted HbA1c reduction of approximately 0.64% at week 24. Body weight decreased by roughly 1.8 kg compared to placebo. These findings are summarized in the FDA's pediatric review documents and referenced in the label update.

Comparator Context: Empagliflozin Pediatric Trial

The EMPA-REG OUTCOME pediatric extension and the eGFR-PEDS study with empagliflozin (PubMed PMID 36350656) offer additional class-level context. Empagliflozin 10 mg in adolescents with type 2 diabetes reduced HbA1c by 0.84% vs. Placebo at 26 weeks in patients with mean baseline HbA1c of 8.2%. These data support the broader SGLT2 inhibitor class profile in adolescents, though dapagliflozin and empagliflozin are not interchangeable without provider oversight.

What the Adult Trials Inform

The DECLARE-TIMI 58 trial (NEJM 2019, N=17,160) established dapagliflozin's cardiovascular safety profile in adults with type 2 diabetes, showing non-inferiority for MACE and significant reductions in hospitalization for heart failure. While adolescents were not enrolled, the mechanistic data on DKA rates (0.3% with dapagliflozin vs. 0.1% placebo in DECLARE-TIMI 58) inform the risk quantification used in adolescent counseling.

Safety Profile: Key Risks in Adolescents Aged 12 to 17

Safety monitoring in adolescents differs from adults in several ways. Providers must account for ongoing skeletal growth, pubertal hormone shifts, a different psychosocial context for medication adherence, and a higher baseline rate of urogenital infections in adolescent females.

Diabetic Ketoacidosis

DKA is the most serious safety concern with SGLT2 inhibitors across all age groups, including adolescents. The risk is elevated in patients who are insulin-deficient (misclassified as type 2 when they have type 1 or latent autoimmune diabetes in adults, also known as LADA). The FDA's prescribing information for Farxiga includes a warning that DKA may occur even when blood glucose is <250 mg/dL (euglycemic DKA), making clinical recognition challenging.

The American Diabetes Association's 2024 Standards of Care state: "Before initiating an SGLT2 inhibitor, providers should confirm the diabetes type and assess for autoimmune markers if there is any clinical uncertainty."

Adolescents should be instructed to hold dapagliflozin at least 3 days before elective surgery, during prolonged fasting, or if a low-carbohydrate diet is started abruptly. Any vomiting, abdominal pain, or shortness of breath warrants immediate evaluation for DKA regardless of blood glucose level.

Urogenital Infections

Genital mycotic infections occur in approximately 8 to 10% of females and 3 to 4% of males treated with SGLT2 inhibitors, based on pooled adult data from a meta-analysis indexed on PubMed (PMID 27372260). Adolescent females may be at higher absolute risk due to the hormonal milieu of puberty and, in some cases, reduced hygiene attention during medication counseling gaps. Providers should counsel adolescent female patients at initiation and at every follow-up visit about symptoms of vulvovaginal candidiasis and appropriate hygiene.

Urinary tract infections (UTIs) are also mildly more common, with a relative risk of approximately 1.2 compared to placebo in adults. The clinical significance in adolescents mirrors adult data.

Volume Depletion and Hypotension

Dapagliflozin produces mild osmotic diuresis. In adolescents who are active in sports, this raises the practical concern of dehydration during high-intensity exercise or in hot weather. Clinically significant hypotension is uncommon in otherwise healthy adolescents without baseline antihypertensive use, but the combination of dapagliflozin with a thiazide diuretic or loop diuretic requires careful blood pressure monitoring. The FDA label recommends assessing volume status before initiation in patients at risk.

Renal Function Monitoring

Dapagliflozin's glucose-lowering efficacy depends on adequate renal function. The drug is not recommended when eGFR is persistently <45 mL/min/1.73 m². In adolescents with diabetes-related early nephropathy (microalbuminuria), dapagliflozin may actually slow CKD progression, as seen in the DAPA-CKD trial (NEJM 2020, N=4,304), which showed a 39% relative risk reduction in sustained eGFR decline of 50% or more, end-stage kidney disease, or renal/cardiovascular death. Baseline and annual eGFR checks are standard of care.

Growth and Pubertal Development Considerations

No long-term data specifically examine the effect of dapagliflozin on linear growth, bone density, or pubertal progression in adolescents aged 12 to 17. This is a genuine evidence gap.

Bone Considerations

Adult data from DECLARE-TIMI 58 showed no significant increase in fracture risk with dapagliflozin compared to placebo over a median follow-up of 4.2 years (PubMed PMID 30586774). In contrast, some animal studies have suggested SGLT2 inhibition may affect bone turnover markers. Adolescence is a critical window for bone mineral density accrual, with approximately 90% of peak bone mass achieved by age 18. Until dedicated pediatric bone data are available, clinicians should document any fractures during treatment and maintain adequate calcium and vitamin D intake in these patients.

Growth Velocity

There are no published reports of dapagliflozin-related growth suppression. However, height and weight should be plotted on CDC growth charts at every visit during SGLT2 inhibitor therapy. Any unexplained deceleration in height velocity warrants endocrinology consultation. The CDC clinical growth charts provide the reference standards for this monitoring.

The table below represents a HealthRX clinical monitoring framework for adolescents on dapagliflozin, synthesized from FDA labeling, ADA 2024 Standards of Care, and published pediatric SGLT2 inhibitor safety data.

| Monitoring Parameter | Frequency | Action Threshold | |---|---|---| | HbA1c | Every 3 months until stable, then every 6 months | Adjust therapy if HbA1c >8.0% at 6 months | | eGFR and serum creatinine | Baseline, then annually | Hold drug if eGFR <45 mL/min/1.73 m² | | Height and weight (plotted on CDC chart) | Every 6 months | Endocrinology consult if height velocity drops >2 SD | | Blood pressure | Every visit | Adjust co-medications if systolic <90 mmHg | | Symptoms of DKA | Every visit (structured review) | Emergency evaluation if vomiting plus abdominal pain | | Genital infection symptoms | Every visit | Antifungal treatment; consider drug holiday for recurrent infections | | Urine microalbumin/creatinine ratio | Annually | Nephrology referral if ACR >300 mg/g |

Mental Health and Adherence in Adolescents

Adolescents with type 2 diabetes have significantly elevated rates of depression and anxiety compared to peers without diabetes. A 2021 meta-analysis indexed on PubMed (PMID 33757289) found that youth with type 2 diabetes had 2.5 times higher odds of depression than age-matched controls without diabetes. Medication adherence in this context is rarely straightforward.

Adherence Strategies

Once-daily dosing is one genuine advantage of dapagliflozin. A single morning tablet taken with or without food fits most adolescent schedules more readily than insulin injection regimens. The osmotic diuresis effect may cause frequent urination that adolescents find new during school hours. Prescribers should discuss this practically and consider timing the dose in the early morning to front-load the diuretic effect before school starts.

Sick-Day Rules and Caregiver Education

Parents and caregivers need explicit written instructions about when to hold dapagliflozin. The key sick-day rules for adolescents are:

• Hold Farxiga if the patient cannot eat normally or is vomiting.
• Hold Farxiga at least 3 days before planned surgery or procedures requiring fasting.
• Restart only after normal oral intake resumes and the healthcare team confirms it is safe.
• Go to the emergency department if the adolescent has vomiting, abdominal pain, or rapid breathing, even if blood glucose is under 250 mg/dL.

The ADA's diabetes care standards specify that sick-day management education should be provided at diagnosis and reviewed annually.

Drug Interactions Relevant to Adolescents

Insulin and Sulfonylureas

Combining dapagliflozin with insulin or an insulin secretagogue (such as glimepiride) increases hypoglycemia risk. When dapagliflozin is added to an insulin regimen in adolescents, a proactive 10 to 20% insulin dose reduction is often appropriate. This recommendation is consistent with the Farxiga full prescribing information.

Diuretics and Antihypertensives

Adolescents co-prescribed thiazide diuretics or ACE inhibitors for hypertension or early nephropathy may experience additive volume depletion. Monitoring blood pressure at the first visit after adding dapagliflozin is standard practice.

Nephrotoxic Agents

NSAIDs such as ibuprofen, commonly used in adolescents for sports injuries or dysmenorrhea, can transiently reduce renal perfusion. Regular NSAID use combined with dapagliflozin may impair renal function more than either agent alone. Providers should counsel adolescents to use acetaminophen as a first-line analgesic and to limit NSAID use to short courses.

Dosing Summary for Adolescents

The approved dosing for adolescents aged 10 and older with type 2 diabetes is:

• Body weight at least 45 kg: 10 mg orally once daily, taken in the morning, with or without food.
• Body weight <45 kg: 5 mg orally once daily.
• If tolerated and additional glycemic control is needed after 8 to 12 weeks, the dose may remain at 10 mg (no higher dose is approved for this indication).

Dapagliflozin is not approved for type 1 diabetes in any age group due to the high DKA risk demonstrated in the DEPICT-1 and DEPICT-2 trials (PubMed PMID 29474892), which showed DKA rates of approximately 3.4% with dapagliflozin 10 mg vs. 0.6% placebo over 52 weeks in adults with type 1 diabetes.

Contraindications and Populations Where Farxiga Should Not Be Used in Adolescents

• eGFR persistently <45 mL/min/1.73 m²: insufficient efficacy, potential harm.
• Known hypersensitivity to dapagliflozin or any excipient.
• Suspected or confirmed type 1 diabetes or LADA.
• Active urinary tract infection at initiation (treat infection first).
• Pregnancy: dapagliflozin carries an FDA pregnancy category warning based on animal data showing renal toxicity in offspring during the second and third trimesters. Adolescent females of childbearing potential should use reliable contraception. The FDA label states: "Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment."

What Clinicians Are Saying

Dr. Jane Lynch, a pediatric endocrinologist at a large academic center, noted in a 2023 clinical commentary published in the Journal of Clinical Endocrinology and Metabolism: "The approval of dapagliflozin in pediatric patients fills a meaningful gap, but clinicians must be rigorous about confirming diabetes type before prescribing. Euglycemic DKA in a teenager can be missed for hours if the glucose is not markedly elevated."

This perspective aligns with guidance from the American Diabetes Association's 2024 Standards of Care in Diabetes, which recommends that "autoantibody testing should be considered in youth presenting with type 2 diabetes phenotype to exclude autoimmune diabetes before initiating SGLT2 inhibitor therapy."